TickerTain — Make Analysis Fun Again

←

▶ 47:00 · Life Sciences & Drug Development · Anti-amyloid antibodies show 30% slowing now; earlier intervention could achieve 40-50%+ reduction, mirroring preventive paradigm in diabetes and CVD

now playing · Life Sciences & Drug Development

Healthcare Systems & Policytailwindscore 9/10alex cornell

Five-layer defensive health stack (lipids, glucose, neuro, inflammation, BP) has existing medicines that could add a decade of life if adoption gaps closed

Medicines exist for all five core drivers of mortality (statins/PCSK9 for lipids, GLP-1s for cardiometabolic, anti-amyloid for neuro, anti-inflammatories, antihypertensives) but systemic fr…

Cardiovascular Diseasetailwindscore 8/10alex cornell

30-50% of middle-aged adults face heart attack/stroke risk; existing PCSK9/statins can lower to <10% but systemic friction prevents uptake

LDL accumulation is silent and asymptomatic until catastrophic event. PCSK9 inhibitors offer superior risk/reward vs statins (genetic evidence of safety at near-zero LDL). Compliance is the…

GLP-1 & Metabolic Drugstailwindscore 9/10alex cornell

Oral GLP-1 at $150/month unlocks mass preventive adoption, proving trillion-dollar health revolution thesis

Price elasticity is extreme: compounded GLP-1s captured 15-20% market at $250/month; oral Wegovy at $150/month drives 4x launch velocity (300k vs 200k new scripts/week). Direct-to-consumer…

Cardiovascular Diseasetailwindscore 8/10alex cornell

PCSK9 inhibitors are a 'free lunch' with 88% CVD risk reduction in genetic models, destined to exceed GLP-1 market long-term

Human genetic knockouts show 88% CVD risk reduction with lifelong PCSK9 deficiency; drugs achieve 50% LDL lowering and 20-25% event reduction in outcome trials. Unlike GLP-1s, minimal side…

Life Sciences & Drug Developmenttailwindscore 7/10alex cornell

Anti-amyloid antibodies show 30% slowing now; earlier intervention could achieve 40-50%+ reduction, mirroring preventive paradigm in diabetes and CVD

Current anti-amyloid drugs (Leqembi, donanemab) clear plaques but treat too late after irreversible neurodegeneration. Biomarker-enabled early detection (blood tests coming) plus earlier do…

Oncologytailwindscore 8/10alex cornell

Blood-based multi-cancer early detection inflecting as Guardant Health's Shield test scales, colonoscopy avoidance creates massive market

Exact Sciences (stool) and Guardant Health (blood) prove commercial viability of non-invasive colorectal screening. Blood test eliminates collection friction, driving inflection. Multi-canc…

AI Drug Discoverytailwindscore 9/10alex cornell

Automated 'science factories' (Lila Sciences, Enabla) achieve model-to-molecule in months, generating proprietary data moats toward scientific superintelligence

Agentic AI + robotic labs compress hit-to-lead from years to months by running 24/7 in silico and physical experiments. Public literature is noisy/irreproducible; winners combine AI talent,…

←

▶ 47:00 · Life Sciences & Drug Development · Anti-amyloid antibodies show 30% slowing now; earlier intervention could achieve 40-50%+ reduction, mirroring preventive paradigm in diabetes and CVD

now playing · Life Sciences & Drug Development

Healthcare Systems & Policytailwindscore 9/10alex cornell

Five-layer defensive health stack (lipids, glucose, neuro, inflammation, BP) has existing medicines that could add a decade of life if adoption gaps closed

Medicines exist for all five core drivers of mortality (statins/PCSK9 for lipids, GLP-1s for cardiometabolic, anti-amyloid for neuro, anti-inflammatories, antihypertensives) but systemic fr…

Cardiovascular Diseasetailwindscore 8/10alex cornell

30-50% of middle-aged adults face heart attack/stroke risk; existing PCSK9/statins can lower to <10% but systemic friction prevents uptake

LDL accumulation is silent and asymptomatic until catastrophic event. PCSK9 inhibitors offer superior risk/reward vs statins (genetic evidence of safety at near-zero LDL). Compliance is the…

GLP-1 & Metabolic Drugstailwindscore 9/10alex cornell

Oral GLP-1 at $150/month unlocks mass preventive adoption, proving trillion-dollar health revolution thesis

Price elasticity is extreme: compounded GLP-1s captured 15-20% market at $250/month; oral Wegovy at $150/month drives 4x launch velocity (300k vs 200k new scripts/week). Direct-to-consumer…

Cardiovascular Diseasetailwindscore 8/10alex cornell

PCSK9 inhibitors are a 'free lunch' with 88% CVD risk reduction in genetic models, destined to exceed GLP-1 market long-term

Human genetic knockouts show 88% CVD risk reduction with lifelong PCSK9 deficiency; drugs achieve 50% LDL lowering and 20-25% event reduction in outcome trials. Unlike GLP-1s, minimal side…

Life Sciences & Drug Developmenttailwindscore 7/10alex cornell

Anti-amyloid antibodies show 30% slowing now; earlier intervention could achieve 40-50%+ reduction, mirroring preventive paradigm in diabetes and CVD

Current anti-amyloid drugs (Leqembi, donanemab) clear plaques but treat too late after irreversible neurodegeneration. Biomarker-enabled early detection (blood tests coming) plus earlier do…

Oncologytailwindscore 8/10alex cornell

Blood-based multi-cancer early detection inflecting as Guardant Health's Shield test scales, colonoscopy avoidance creates massive market

Exact Sciences (stool) and Guardant Health (blood) prove commercial viability of non-invasive colorectal screening. Blood test eliminates collection friction, driving inflection. Multi-canc…

AI Drug Discoverytailwindscore 9/10alex cornell

Automated 'science factories' (Lila Sciences, Enabla) achieve model-to-molecule in months, generating proprietary data moats toward scientific superintelligence

Agentic AI + robotic labs compress hit-to-lead from years to months by running 24/7 in silico and physical experiments. Public literature is noisy/irreproducible; winners combine AI talent,…